Cargando…

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

IMPORTANCE: The COVID-19 pandemic has been associated with substantial reduction in screening, case identification, and hospital referrals among patients with cancer. However, no study has quantitatively examined the implications of this correlation for cancer patient management. OBJECTIVE: To evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thierry, Alain R., Pastor, Brice, Pisareva, Ekaterina, Ghiringhelli, Francois, Bouché, Olivier, De La Fouchardière, Christelle, Vanbockstael, Julie, Smith, Denis, François, Eric, Dos Santos, Mélanie, Botsen, Damien, Ellis, Stephen, Fonck, Marianne, André, Thierry, Guardiola, Emmanuel, Khemissa, Faiza, Linot, Benjamin, Martin-Babau, J., Rinaldi, Yves, Assenat, Eric, Clavel, Lea, Dominguez, Sophie, Gavoille, Celine, Sefrioui, David, Pezzella, Veronica, Mollevi, Caroline, Ychou, Marc, Mazard, Thibault
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427376/ https://www.ncbi.nlm.nih.gov/pubmed/34495337 http://dx.doi.org/10.1001/jamanetworkopen.2021.24483

Ejemplares similares

Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study
por: Mazard, Thibault, et al.
Publicado: (2021)

Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial
por: Assenat, E., et al.
Publicado: (2021)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer
por: Pastor, Brice, et al.
Publicado: (2022)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
por: Bidard, François-Clément, et al.
Publicado: (2019)

Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2009)

A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer
por: Grosgeorges, Marie, et al.
Publicado: (2023)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics
por: Sanchez, Cynthia, et al.
Publicado: (2021)

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
por: Samalin, E, et al.
Publicado: (2014)

Comparison of the structures and topologies of plasma extracted circulating nuclear and mitochondrial cell-free DNA
por: Pisareva, Ekaterina, et al.
Publicado: (2023)

Machine Learning‐Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening
por: Tanos, Rita, et al.
Publicado: (2020)

Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones
por: Cayrefourcq, Laure, et al.
Publicado: (2021)

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
por: Kim, Stefano, et al.
Publicado: (2020)

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
por: Kim, Stefano, et al.
Publicado: (2022)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2012)

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma
por: Kim, Stefano, et al.
Publicado: (2020)

Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA
por: Pisareva, Ekaterina, et al.
Publicado: (2022)

Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study
por: Bordeau, Karl, et al.
Publicado: (2022)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX)
por: Martin, Pierre, et al.
Publicado: (2022)

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients
por: Palle, Juliette, et al.
Publicado: (2021)

Accuracy of height estimation and tidal volume setting using anthropometric formulas in an ICU Caucasian population
por: L’her, Erwan, et al.
Publicado: (2016)

Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
por: Ali, Raafi, et al.
Publicado: (2016)

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes
por: Soler, Alexandra, et al.
Publicado: (2018)

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
por: de Rauglaudre, Bernadette, et al.
Publicado: (2022)

Specific Extracellular Matrix Remodeling Signature of Colon Hepatic Metastases
por: Del Rio, Maguy, et al.
Publicado: (2013)

Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
por: Bordeau, Karl, et al.
Publicado: (2023)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017)

The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
por: You, Benoit, et al.
Publicado: (2019)

Prognostic value of Lynch syndrome, BRAF(V600E) , and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
por: Zwart, Koen, et al.
Publicado: (2023)

Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study
por: Lemoine, Amélie, et al.
Publicado: (2022)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers
por: Evrard, Camille, et al.
Publicado: (2022)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Deletion of Apoptosis Signal-Regulating Kinase 1 (ASK1) Protects Pancreatic Beta-Cells from Stress-Induced Death but Not from Glucose Homeostasis Alterations under Pro-Inflammatory Conditions
por: Pepin, Emilie, et al.
Publicado: (2014)

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
por: Palle, Juliette, et al.
Publicado: (2017)

Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients
por: Botsen, Damien, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tsn99428t9q8k4e8m8qi67dcba